Results: 1-3 |
Results: 3

Authors: Babiker, A Darby, S De Angelis, D Kwart, D Porter, K Beral, V Darbyshire, J Day, N Gill, N Coutinho, R Prins, M van Benthem, B Coutinho, R Dabis, F Marimoutou, C Ruiz, I Tusell, J Altisent, C Evatt, B Jaffe, H Kirk, O Pedersen, C Rosenberg, P Goedert, J Biggar, R Melbye, M Brettie, R Downs, A Hamouda, O Touloumi, G Karafoulidou, A Katsarou, O Donfield, S Gomperts, E Hilgartner, M Hoots, K Schoenbaum, E Beral, V Zangerle, R Del Amo, J Pezzotti, P Rezza, G Hutchinson, S Day, N De Angelis, D Gore, S Kingsley, L Schrager, L Rosenberg, P Goedert, J Melnick, S Koblin, B Eskild, A Bruun, J Sannes, M Evans, B Lepri, AC Sabin, C Buchbinder, S Vittinghoff, E Moss, A Osmond, D Winkelstein, W Goldberg, D Boufassa, F Meyer, L Egger, M Francioli, P Rickenbach, M Cooper, D Tindall, B Sharkey, T Vizzard, J Kaldor, J Cunningham, P Vanhems, P Vizzard, J Kaldor, J Learmont, J Farewell, V Berglund, O Mosley, J Operskalski, E van den Berg, M Metzger, D Tobin, D Woody, G Rusnak, J Hendrix, C Garner, R Hawkes, C Renzullo, P Garland, F Darby, S Ewart, D Giangrande, P Lee, C Phillips, A Spooner, R Wilde, J Winter, M Babiker, A Darbyshire, J Evans, B Gill, N Johnson, A Phillips, A Porter, K Lorenzo, JI Schechter, M
Citation: A. Babiker et al., Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis, LANCET, 355(9210), 2000, pp. 1131-1137

Authors: Abrams, D Allan, D Antunes, F Breckenridge, A Bruun, J Cameron, W Carbon, C Chalmers, I Chang, H Chodakewitz, J Clendenin, N Clumeck, N Collier, A Collins, G Cooper, E Cooper, D Danner, S D'Aquila, R DeGruttola, V DeMasi, R Dee, L Deyton, L Dixon, D Farthing, C Feinberg, J Fischl, M Flepp, M Gartland, M Gatell, J Gazzard, B Goebel, F Gotzsche, P Gringeri, A Hall, D Hamilton, J Hammer, S Hartigan, P Heath-Chiozzi, M Henry, K Hill, A Hirschel, B Ioannidis, J Kahn, J Katlama, C Katzenstein, D Killen, J King, E de Loes, SK Kravcik, S Lange, J Leavitt, R Leonard, J Maeland, A Mannucci, P Mathiesen, L McDade, H Meibohn, A Melander, H Merigan, T Mulder, J Myers, M Neaton, J Nessling, M Perrin, L Pettinelli, C Phair, J Phillips, A Pinching, A Poppa, A Power, L Reiss, P Richman, D Rooney, J Rousseau, F Rutherford, G Salgo, M Sandstrom, E Saravolatz, L Savidge, G Schnittman, S Schooley, R Seligmann, M Simberkoff, M Skowron, G Slade, P Smith, D Smith, RP Soriano, V Stanley, K Stingl, G Stoffels, P Struthers, L Tierney, C Thompson, M Van der Broeck, R Van Leeuven, R Van Weverling, G Veenstra, J Vella, S Volberding, P Weber, J Winslow, D Yeni, P Yeo, J Dormont, J Sande, M Weller, I Babiker, A Collins, R Darbyshire, J Duncan, W Foulkes, M Hughes, M Peto, R Peto, T Walker, S
Citation: D. Abrams et al., Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection:meta-analyses of the randomised evidence, LANCET, 353(9169), 1999, pp. 2014-2025

Authors: Bodker, A Bruun, J Balslev, E Iversen, HG Meyhoff, HH Andersson, KE
Citation: A. Bodker et al., Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia, SC J UROL N, 33(4), 1999, pp. 237-242
Risultati: 1-3 |